Cargando…

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

BACKGROUNDS: Gene polymorphisms are critical for variations in warfarin dose. To date, more than 70 CYP2C9 alleles have been identified. This study was designed to clarify the clinical significance of CYP2C9*non-3 variants to warfarin sensitivity in Chinese Han patients. METHODS: The entire CYP2C9 g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dongxu, Wu, Hualan, Dong, Min, Zhang, Qing, Zhao, Anxu, Zhao, Xinlong, Chong, Jia, Du, Minghui, Wang, Yan, Shi, Haifeng, Wang, Shuanghu, Wang, Fang, Cai, Jianping, Yang, Jiefu, Dai, Dapeng, Chen, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729276/ https://www.ncbi.nlm.nih.gov/pubmed/36505370 http://dx.doi.org/10.3389/fcvm.2022.1052521

Ejemplares similares

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects
por: Zhang, Qing, et al.
Publicado: (2023)

Helicobacter pylori and unignorable extragastric diseases: Mechanism and implications
por: He, Junjian, et al.
Publicado: (2022)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Diurnal Variation of Epiphytic Microbiota: an Unignorable Factor Affecting the Anaerobic Fermentation Characteristics of Sorghum-Sudangrass Hybrid Silage
por: Dong, Zhihao, et al.
Publicado: (2022)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections
por: Lu, Linli, et al.
Publicado: (2022)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Long Short-Term Memory Network for Development and Simulation of Warfarin Dosing Model Based on Time Series Anticoagulant Data
por: Kuang, Yun, et al.
Publicado: (2022)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model
por: Zhu, Zhihui, et al.
Publicado: (2019)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Effects of propolis on warfarin efficacy
por: Akbay, Esin, et al.
Publicado: (2017)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Prevalence, Predictors, and Clinical Presentation of Acute Pericardial Effusion Following Percutaneous Coronary Intervention
por: Zhao, Bei, et al.
Publicado: (2022)

Short-term warfarin treatment for apical thrombus in a patient with Takotsubo cardiomyopathy
por: İcli, Abdullah, et al.
Publicado: (2016)

Capecitabine and Warfarin Interaction: A Case Report With Review of Literature and Management Options
por: Althiab, Khalefa, et al.
Publicado: (2022)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease
por: Dai, Ruozhu, et al.
Publicado: (2022)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020)

Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area
por: Njovane, Xolani W, et al.
Publicado: (2013)

Expression Profiles of Circular RNA in Human Atrial Fibrillation With Valvular Heart Diseases
por: Zhu, Xiyu, et al.
Publicado: (2020)

Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials
por: Liu, Fuwei, et al.
Publicado: (2022)

Effect of codeine on CYP450 isoform activity of rats
por: Wang, Shuanghu, et al.
Publicado: (2017)

VKORC1 variants as significant predictors of warfarin dose in Emiratis
por: Al-Mahayri, Zeina N, et al.
Publicado: (2019)

A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa
por: Jacobs,, Annemarie, et al.
Publicado: (2017)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients
por: Feng, Qiang, et al.
Publicado: (2022)

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol
por: Li, Guowei, et al.
Publicado: (2015)

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China
por: Yang, Li, et al.
Publicado: (2020)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis
por: Tsai, Sung Huang Laurent, et al.
Publicado: (2022)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Elfar, Sohil, et al.
Publicado: (2022)

Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
por: Zeng, Shan, et al.
Publicado: (2022)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
por: He, Shiwei, et al.
Publicado: (2021)

Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience
por: Abelson, Mark
Publicado: (2013)

Comparison of the outcomes of warfarin therapy and economics by online and offline anticoagulation management models: protocol for a randomised controlled trial
por: Xia, Xiaotong, et al.
Publicado: (2019)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4i6qavttm9r67gitc0evoiv0j2